Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2011

Document Sample
Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2011 Powered By Docstoc
					Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2011




    Islet Cell Carcinoma (Insulinoma) – Pipeline Review,
                           H2 2011

                                                                                          Reference Code: GMDHC1603IDB
                                                                                          Publication Date: December 2011




Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2011                              GMDHC1603IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2011




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
    Global Markets Direct Report Coverage ........................................................................................................................................ 6
Islet Cell Carcinoma (Insulinoma) Overview ....................................................................................................................................... 7
Therapeutics Development................................................................................................................................................................. 8
    An Overview of Pipeline Products for Islet Cell Carcinoma (Insulinoma)....................................................................................... 8
Islet Cell Carcinoma (Insulinoma) Therapeutics under Development by Companies ....................................................................... 10
Islet Cell Carcinoma (Insulinoma) Therapeutics under Investigation by Universities/Institutes ........................................................ 11
Mid Clinical Stage Products.............................................................................................................................................................. 13
    Comparative Analysis .................................................................................................................................................................. 13
Early Clinical Stage Products ........................................................................................................................................................... 14
    Comparative Analysis .................................................................................................................................................................. 14
Pre-Clinical Stage Products.............................................................................................................................................................. 15
    Comparative Analysis .................................................................................................................................................................. 15
Islet Cell Carcinoma (Insulinoma) Therapeutics – Products under Development by Companies ..................................................... 16
Islet Cell Carcinoma (Insulinoma) Therapeutics – Products under Investigation by Universities/Institutes ...................................... 17
Companies Involved in Islet Cell Carcinoma (Insulinoma) Therapeutics Development .................................................................... 18
    Novartis AG ................................................................................................................................................................................. 18
    ImClone Systems Incorporated ................................................................................................................................................... 19
    ImmunoGen, Inc. ......................................................................................................................................................................... 20
    Threshold Pharmaceuticals, Inc. ................................................................................................................................................. 21
    Virobay Inc................................................................................................................................................................................... 22
Islet Cell Carcinoma (Insulinoma) – Therapeutics Assessment........................................................................................................ 23
    Assessment by Monotherapy Products ....................................................................................................................................... 23
    Assessment by Combination Products ........................................................................................................................................ 24
    Assessment by Route of Administration ...................................................................................................................................... 25
    Assessment by Molecule Type .................................................................................................................................................... 27
Drug Profiles..................................................................................................................................................................................... 29
    IMGN901 - Drug Profile ............................................................................................................................................................... 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    VBY-825 - Drug Profile ................................................................................................................................................................ 31
         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31
         R&D Progress ......................................................................................................................................................................... 31
    Sorafenib + RAD001 - Drug Profile ............................................................................................................................................. 32
         Product Description................................................................................................................................................................. 32
         Mechanism of Action ............................................................................................................................................................... 32
         R&D Progress ......................................................................................................................................................................... 32



Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2011                                                                              GMDHC1603IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2011



    Bevacizumab + Temozolomide - Drug Profile ............................................................................................................................. 34
        Product Description................................................................................................................................................................. 34
        Mechanism of Action ............................................................................................................................................................... 34
        R&D Progress ......................................................................................................................................................................... 34
    AMG 706 + Octreotide - Drug Profile ........................................................................................................................................... 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 36
    Temsirolimus + Bevacizumab - Drug Profile................................................................................................................................ 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progress ......................................................................................................................................................................... 38
    AMG 479 - Drug Profile ............................................................................................................................................................... 39
        Product Description................................................................................................................................................................. 39
        Mechanism of Action ............................................................................................................................................................... 39
        R&D Progress ......................................................................................................................................................................... 39
    Thalidomide - Drug Profile ........................................................................................................................................................... 40
        Product Description................................................................................................................................................................. 40
        Mechanism of Action ............................................................................................................................................................... 40
        R&D Progress ......................................................................................................................................................................... 40
    ZD1839 - Drug Profile.................................................................................................................................................................. 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    Lithium Carbonate - Drug Profile ................................................................................................................................................. 42
        Product Description................................................................................................................................................................. 42
        Mechanism of Action ............................................................................................................................................................... 42
        R&D Progress ......................................................................................................................................................................... 42
    FOLFIRI - Drug Profile ................................................................................................................................................................. 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ...........................................................
				
DOCUMENT INFO
Description: Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Islet Cell Carcinoma (Insulinoma) - Pipeline Review, H2 2011', provides an overview of the Islet Cell Carcinoma (Insulinoma) therapeutic pipeline. This report provides information on the therapeutic development for Islet Cell Carcinoma (Insulinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Islet Cell Carcinoma (Insulinoma). 'Islet Cell Carcinoma (Insulinoma) - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Islet Cell Carcinoma (Insulinoma). - A review of the Islet Cell Carcinoma (Insulinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Islet Cell Carcinoma (Insulinoma) pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries